HB1552 would require several categories of health coverage in Indiana to include benefits for obesity treatment. Specifically, it directs state employee health plans, policies of accident and sickness insurance, and health maintenance organization contracts to cover anti-obesity medication and intensive behavioral and lifestyle therapy. The bill defines anti-obesity medication as FDA-approved medication prescribed by a physician to help an individual achieve and maintain a healthy weight, and it defines intensive behavioral and lifestyle therapy as counseling or treatment focused on changing lifestyle and behavioral habits and managing or treating obesity.
The coverage mandate would apply only to plans and contracts established, issued, delivered, amended, or renewed after June 30, 2025, with an effective date of July 1, 2025. The bill amends Indiana insurance law and state employee health plan statutes by adding new provisions to the Indiana Code that require these benefits to be included going forward. In practical terms, it would expand mandated health benefits for both public employee coverage and private insurance products regulated by the state.
Impact
HB1552 would create new coverage requirements in Indiana law for anti-obesity medication and intensive behavioral and lifestyle therapy across state employee health plans, accident and sickness insurance policies, and HMO contracts. It would add new sections to IC 5-10-8, IC 27-8-40.2, and IC 27-13-7-30, thereby expanding mandated benefits for insurers and public plans subject to state regulation. The bill would likely affect plan design, premiums, utilization management, and access to obesity treatment services for covered individuals.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a health coverage expansion aimed at treating obesity as a chronic disease. The caption and structure suggest a supportive policy approach toward improving access to treatment. No committee transcript or vote record is available here, so there is no documented public debate in the provided materials, but the bill’s introduction indicates legislative interest in requiring broader insurance coverage for obesity-related care.
Contention
The main likely point of contention is the cost and scope of a mandated benefit. Insurers, employers, and state plan administrators may be concerned about premium increases, higher utilization, and whether anti-obesity medications should be covered broadly as a required benefit. Supporters would likely emphasize access to medically necessary treatment, while critics may question affordability, long-term effectiveness, and whether the mandate should apply to all plans and contracts. No specific objections or amendments are included in the provided record.